Organon & Co
OGN9.710USD
-0.040-0.41%
交易中 （美東）報價延遲15分鐘
2.50B總市值
3.34本益比TTM
關於 Organon & Co 公司
Organon & Co. 是一家全球醫療保健公司。該公司致力於通過一系列處方療法和女性健康領域的醫療設備、生物仿製藥以及一系列治療領域的成熟藥物特許經營權來開發和提供健康解決方案。該公司擁有一系列避孕和生育品牌，包括 Nexplanon、NuvaRing 和 Follistim AQ。其生物仿製藥產品組合涵蓋免疫學和腫瘤學治療。該公司還擁有一系列成熟品牌，包括心血管、皮膚病學和非阿片類止痛藥領域的品牌。該公司通過各種渠道銷售這些產品，包括藥品批發商和零售商、醫院、政府機構和管理醫療保健提供商，如藥房福利管理機構和其他機構。該公司的產品組合還包括 1% VTAMA（tapinarof）乳膏，這是一種非生物、非甾體外用療法，用於治療成人輕度、中度和重度斑塊狀銀屑病。
公司簡介
公司代碼OGN
公司名稱Organon & Co
上市日期May 14, 2021
CEOMr. Kevin Ali
員工數量10000
證券類型Ordinary Share
年結日May 14
公司地址30 Hudson Street
城市JERSEY CITY
上市交易所NYSE Consolidated
國家United States of America
郵編07302
電話15514306000
網址https://www.organon.com/
公司代碼OGN
上市日期May 14, 2021
CEOMr. Kevin Ali
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. Kevin Ali
Mr. Kevin Ali
Chief Executive Officer, Director
Chief Executive Officer, Director
282.73K
+13.67%
Mr. Matthew M. (Matt) Walsh
Mr. Matthew M. (Matt) Walsh
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
144.48K
+8.57%
Ms. Rachel A. Stahler
Ms. Rachel A. Stahler
Executive Vice President, Chief Digital and Growth Officer
Executive Vice President, Chief Digital and Growth Officer
71.89K
+18.29%
Mr. Aaron Falcione
Mr. Aaron Falcione
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
59.92K
+10.11%
Mr. Kirke Weaver
Mr. Kirke Weaver
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
52.85K
+17.96%
Mr. Vittorio Nisita
Mr. Vittorio Nisita
Executive Vice President, Head of Enterprise Services & Solutions
Executive Vice President, Head of Enterprise Services & Solutions
41.33K
+26.65%
Ms. Rochelle B. (Shelly) Lazarus
Ms. Rochelle B. (Shelly) Lazarus
Independent Director
Independent Director
633.00
--
Ms. Shalini Sharp
Ms. Shalini Sharp
Independent Director
Independent Director
2.00
--
Ms. Ramona A. Sequeira
Ms. Ramona A. Sequeira
Independent Director
Independent Director
--
--
Mr. Robert A. (Bob) Essner
Mr. Robert A. (Bob) Essner
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Kevin Ali
Mr. Kevin Ali
Chief Executive Officer, Director
Chief Executive Officer, Director
282.73K
+13.67%
Mr. Matthew M. (Matt) Walsh
Mr. Matthew M. (Matt) Walsh
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
144.48K
+8.57%
Ms. Rachel A. Stahler
Ms. Rachel A. Stahler
Executive Vice President, Chief Digital and Growth Officer
Executive Vice President, Chief Digital and Growth Officer
71.89K
+18.29%
Mr. Aaron Falcione
Mr. Aaron Falcione
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
59.92K
+10.11%
Mr. Kirke Weaver
Mr. Kirke Weaver
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
52.85K
+17.96%
Mr. Vittorio Nisita
Mr. Vittorio Nisita
Executive Vice President, Head of Enterprise Services & Solutions
Executive Vice President, Head of Enterprise Services & Solutions
41.33K
+26.65%
收入明細
單位: USD更新時間: 7月6日 週日
單位: USD更新時間: 7月6日 週日
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
業務USD
名稱
營收
佔比
Women’s Health
463.00M
30.60%
Cardiovascular
274.00M
18.11%
Respiratory
236.00M
15.60%
Non-Opioid Pain, Bone and Dermatology
217.00M
14.34%
Other
182.00M
12.03%
Biosimilars
141.00M
9.32%
地區USD
名稱
營收
佔比
United States
412.00M
27.23%
Europe and Canada
376.00M
24.85%
Asia Pacific and Japan
251.00M
16.59%
Latin America, Middle East, Russia and Africa
240.00M
15.86%
China
204.00M
13.48%
Other
30.00M
1.98%
業務
地區
業務USD
名稱
營收
佔比
Women’s Health
463.00M
30.60%
Cardiovascular
274.00M
18.11%
Respiratory
236.00M
15.60%
Non-Opioid Pain, Bone and Dermatology
217.00M
14.34%
Other
182.00M
12.03%
Biosimilars
141.00M
9.32%
股東統計
更新時間: 6月2日 週一
更新時間: 6月2日 週一
持股股東
股東類型
持股股東
持股股東
佔比
The Vanguard Group, Inc.
11.39%
BlackRock Institutional Trust Company, N.A.
11.12%
MFS Investment Management
4.07%
State Street Global Advisors (US)
3.45%
LSV Asset Management
3.07%
Other
66.90%
持股股東
持股股東
佔比
The Vanguard Group, Inc.
11.39%
BlackRock Institutional Trust Company, N.A.
11.12%
MFS Investment Management
4.07%
State Street Global Advisors (US)
3.45%
LSV Asset Management
3.07%
Other
66.90%
股東類型
持股股東
佔比
Investment Advisor
51.44%
Investment Advisor/Hedge Fund
19.39%
Hedge Fund
3.75%
Research Firm
2.31%
Pension Fund
1.95%
Sovereign Wealth Fund
0.78%
Bank and Trust
0.65%
Individual Investor
0.35%
Family Office
0.05%
Other
19.34%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
1525
209.67M
80.65%
-45.17M
2025Q1
1611
213.21M
82.04%
-52.34M
2024Q4
1647
218.39M
84.67%
-40.43M
2024Q3
1625
211.80M
82.26%
-47.57M
2024Q2
1676
208.67M
81.14%
-51.47M
2024Q1
1700
205.29M
80.30%
-45.21M
2023Q4
1767
202.90M
79.38%
-24.07M
2023Q3
1835
205.61M
80.45%
-25.35M
2023Q2
2016
205.94M
80.75%
-21.55M
2023Q1
2044
204.79M
80.50%
-21.41M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
The Vanguard Group, Inc.
29.61M
11.39%
-704.86K
-2.33%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
28.91M
11.12%
-948.87K
-3.18%
Mar 31, 2025
MFS Investment Management
10.58M
4.07%
+827.89K
+8.49%
Mar 31, 2025
State Street Global Advisors (US)
8.98M
3.45%
-358.52K
-3.84%
Mar 31, 2025
LSV Asset Management
7.98M
3.07%
+455.70K
+6.06%
Mar 31, 2025
Sound Shore Management, Inc.
4.98M
1.91%
+8.42K
+0.17%
Mar 31, 2025
Nordea Funds Oy
4.85M
1.87%
-1.89M
-28.08%
Mar 31, 2025
DePrince, Race & Zollo, Inc.
4.65M
1.79%
-78.17K
-1.65%
Mar 31, 2025
Geode Capital Management, L.L.C.
4.52M
1.74%
+257.09K
+6.03%
Mar 31, 2025
Dimensional Fund Advisors, L.P.
4.17M
1.6%
+884.26K
+26.92%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
SPDR S&P Pharmaceuticals ETF
3.68%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
2.61%
First Trust NASDAQ Pharmaceuticals ETF
1.89%
Invesco S&P SmallCap Health Care ETF
1.8%
KFA Value Line Dynamic Core Equity Index ETF
1.51%
Global X SuperDividend U.S. ETF
1.36%
Alger Russell Innovation ETF
1.3%
iShares U.S. Pharmaceuticals ETF
1.27%
Amplify Cash Flow Dividend Leaders ETF
1.22%
Amplify Cash Flow High Income ETF
1.21%
查看更多
SPDR S&P Pharmaceuticals ETF
佔比3.68%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
佔比2.61%
First Trust NASDAQ Pharmaceuticals ETF
佔比1.89%
Invesco S&P SmallCap Health Care ETF
佔比1.8%
KFA Value Line Dynamic Core Equity Index ETF
佔比1.51%
Global X SuperDividend U.S. ETF
佔比1.36%
Alger Russell Innovation ETF
佔比1.3%
iShares U.S. Pharmaceuticals ETF
佔比1.27%
Amplify Cash Flow Dividend Leaders ETF
佔比1.22%
Amplify Cash Flow High Income ETF
佔比1.21%
分紅派息
近5年累計派現
1.03B
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
Feb 13, 2025
OGN.NB Interim Cash Dividend of gross USD 0.28 paid on Mar 13, 2025 going ex on Feb 24, 2025
Feb 24, 2025
Mar 13, 2025
Feb 24, 2025
Oct 31, 2024
OGN.NB Final Cash Dividend of gross USD 0.28 paid on Dec 12, 2024 going ex on Nov 12, 2024
Nov 12, 2024
Dec 12, 2024
Nov 12, 2024
Aug 06, 2024
OGN.NB Interim Cash Dividend of gross USD 0.28 paid on Sep 12, 2024 going ex on Aug 16, 2024
Aug 16, 2024
Sep 12, 2024
Aug 16, 2024
May 02, 2024
OGN.NB Interim Cash Dividend of gross USD 0.28 paid on Jun 13, 2024 going ex on May 10, 2024
May 13, 2024
Jun 13, 2024
May 10, 2024
Feb 15, 2024
OGN.NB Interim Cash Dividend of gross USD 0.28 paid on Mar 14, 2024 going ex on Feb 23, 2024
Feb 26, 2024
Mar 14, 2024
Feb 23, 2024
Nov 02, 2023
OGN.NB Final Cash Dividend of gross USD 0.28 paid on Dec 14, 2023 going ex on Nov 10, 2023
Nov 13, 2023
Dec 14, 2023
Nov 10, 2023
Aug 08, 2023
OGN.NB Interim Cash Dividend of gross USD 0.28 paid on Sep 14, 2023 going ex on Aug 17, 2023
Aug 18, 2023
Sep 14, 2023
Aug 17, 2023
May 04, 2023
OGN.NB Interim Cash Dividend of gross USD 0.28 paid on Jun 15, 2023 going ex on May 12, 2023
May 15, 2023
Jun 15, 2023
May 12, 2023
Feb 16, 2023
OGN.NB Interim Cash Dividend of gross USD 0.28 paid on Mar 16, 2023 going ex on Feb 24, 2023
Feb 27, 2023
Mar 16, 2023
Feb 24, 2023
Nov 03, 2022
OGN.NB Final Cash Dividend of gross USD 0.28 paid on Dec 15, 2022 going ex on Nov 10, 2022
Nov 14, 2022
Dec 15, 2022
Nov 10, 2022
查看更多
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
